JP2019523236A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523236A5
JP2019523236A5 JP2018567628A JP2018567628A JP2019523236A5 JP 2019523236 A5 JP2019523236 A5 JP 2019523236A5 JP 2018567628 A JP2018567628 A JP 2018567628A JP 2018567628 A JP2018567628 A JP 2018567628A JP 2019523236 A5 JP2019523236 A5 JP 2019523236A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
beta
lactamase
billed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018567628A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523236A (ja
JP7516007B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/039672 external-priority patent/WO2018005606A1/en
Publication of JP2019523236A publication Critical patent/JP2019523236A/ja
Publication of JP2019523236A5 publication Critical patent/JP2019523236A5/ja
Priority to JP2022074289A priority Critical patent/JP7530933B2/ja
Application granted granted Critical
Publication of JP7516007B2 publication Critical patent/JP7516007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018567628A 2016-06-28 2017-06-28 経口抗生物質からのマイクロバイオーム防御 Active JP7516007B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022074289A JP7530933B2 (ja) 2016-06-28 2022-04-28 経口抗生物質からのマイクロバイオーム防御

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355599P 2016-06-28 2016-06-28
US62/355,599 2016-06-28
PCT/US2017/039672 WO2018005606A1 (en) 2016-06-28 2017-06-28 Microbiome protection from oral antibiotics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022074289A Division JP7530933B2 (ja) 2016-06-28 2022-04-28 経口抗生物質からのマイクロバイオーム防御

Publications (3)

Publication Number Publication Date
JP2019523236A JP2019523236A (ja) 2019-08-22
JP2019523236A5 true JP2019523236A5 (https=) 2020-07-30
JP7516007B2 JP7516007B2 (ja) 2024-07-16

Family

ID=60787676

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018567628A Active JP7516007B2 (ja) 2016-06-28 2017-06-28 経口抗生物質からのマイクロバイオーム防御
JP2022074289A Active JP7530933B2 (ja) 2016-06-28 2022-04-28 経口抗生物質からのマイクロバイオーム防御

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022074289A Active JP7530933B2 (ja) 2016-06-28 2022-04-28 経口抗生物質からのマイクロバイオーム防御

Country Status (5)

Country Link
US (3) US11517614B2 (https=)
EP (1) EP3474885B8 (https=)
JP (2) JP7516007B2 (https=)
CN (1) CN109562147B (https=)
WO (1) WO2018005606A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7168558B2 (ja) 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
WO2020037271A1 (en) * 2018-08-17 2020-02-20 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
ES2994844T3 (en) * 2018-12-07 2025-02-03 Tillotts Pharma Ag Colonic drug delivery formulation
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
ES3002632T3 (en) 2018-12-07 2025-03-07 Tillotts Pharma Ag Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101795675A (zh) * 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
US8273376B2 (en) * 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
FI119678B (fi) * 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
FI20105572A0 (fi) * 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
AU2014239883B2 (en) * 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US9290754B2 (en) * 2014-04-17 2016-03-22 Synthetic Biologics Inc. Beta-lactamases with improved properties for therapy
CN107148473B (zh) 2014-10-08 2021-08-06 合成生物制品有限公司 β-内酰胺酶制剂及其用途
AU2016222936B2 (en) 2015-02-23 2022-01-06 Theriva Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome

Similar Documents

Publication Publication Date Title
JP2019523236A5 (https=)
CA2904389C (en) Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
ES2649063T3 (es) Formulaciones farmacéuticas que contienen rifaximina, procedimientos para su obtención y método de tratamiento de la enfermedad intestinal
US11141440B2 (en) Pharmaceutical oral formulation comprising bacteria
HK1259347A1 (zh) 治疗结肠炎的方法
RS54991B1 (sr) Formulacije za oralnu isporuku adsorbenata u creva
RU2671400C2 (ru) Фармацевтические композиции для лечения от helicobacter pylori
JP2012520268A (ja) グラム陰性細菌の除去のための組成物及び方法
WO2011082218A1 (en) Compositions and method for treatment and prophylaxis of inflammatory bowel disease
RU2744576C2 (ru) Пероральные фармацевтические композиции месалазина
WO2001076635A1 (en) Preparations for preventing bile acid diarrhea
US20150202238A1 (en) Compositions and method for treatment and prophylaxis of inflammatory bowel disease
WO2014011233A1 (en) Compositions and method for treatment and prophylaxis of inflammatory bowel disease
JP2026035819A (ja) 移植片対宿主病の処置のためのβ－ラクタマーゼ組成物
WO2018129061A1 (en) Antimicrobial delivery system for the prevention and treatment of infections in the colon
US20240374526A1 (en) Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US20220054452A1 (en) Duloxetine sprinkles
TWI536989B (zh) 硝呋太爾用於製備治療梭菌屬種所引起之感染之藥物的用途
WO2016108180A2 (en) Process for formulating acid stabilized oral bacterial vaccine
WO2022066110A1 (en) Pharmaceutical compositions comprising mesalamin and relevant excipients